S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
Log in
ASX:IMU

Imugene Limited (IMU.AX) Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
A$0.03
MA: A$0.03
A$0.03
52-Week Range N/A
Volume12.70 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; B-Vaxx, a cancer vaccine to treat tumors that over-express the HER2/neu receptor; and CF-33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. Imugene Limited was incorporated in 1986 and is headquartered in Sydney, Australia.

MarketRank

Overall MarketRank

0.58 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 3 9824 5254
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.13 million
Book ValueA$0.01 per share

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

Receive IMU News and Ratings via Email

Sign-up to receive the latest news and ratings for IMU and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Imugene Limited (IMU.AX) (ASX:IMU) Frequently Asked Questions

What stocks does MarketBeat like better than Imugene Limited (IMU.AX)?

Wall Street analysts have given Imugene Limited (IMU.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Imugene Limited (IMU.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Imugene Limited (IMU.AX)'s earnings last quarter?

Imugene Limited (IMU.AX) (ASX:IMU) released its quarterly earnings data on Thursday, February, 28th. The company reported $0.00 EPS for the quarter.
View Imugene Limited (IMU.AX)'s earnings history
.

Who are some of Imugene Limited (IMU.AX)'s key competitors?

What other stocks do shareholders of Imugene Limited (IMU.AX) own?

Who are Imugene Limited (IMU.AX)'s key executives?

Imugene Limited (IMU.AX)'s management team includes the following people:
  • Mr. Paul Edward-Alexander Hopper, Exec. Chairman (Age 64, Pay $137.4k)
  • Ms. Leslie Chong, CEO, MD & Exec. Director
  • Dr. Nicholas J. Ede, CTO & COO
  • Mr. Phillip Allen Hains, CFO & Joint Company Sec. (Age 61)
  • Dr. Rita Laeufle M.D., Ph.D., Chief Medical Officer
  • Mr. Justyn Peter Stedwell B.Com., B.Com, Joint Company Sec.

What is Imugene Limited (IMU.AX)'s stock symbol?

Imugene Limited (IMU.AX) trades on the ASX under the ticker symbol "IMU."

How big of a company is Imugene Limited (IMU.AX)?

Imugene Limited (IMU.AX) has a market capitalization of $0.00 and generates $4.13 million in revenue each year.

What is Imugene Limited (IMU.AX)'s official website?

The official website for Imugene Limited (IMU.AX) is www.imugene.com.

How can I contact Imugene Limited (IMU.AX)?

The company can be reached via phone at 61 3 9824 5254.

This page was last updated on 1/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.